Showing results (121-130 of 280) with videos related to

Sort By:
Pageof 28
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Leukemia Research|September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclaxJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
British Journal of Cancer|May 17, 2018
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancersJorge Cortes, Kenji Tamura, Daniel J DeAngelo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2021
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22Hagop M Kantarjian, Wendy Stock, Ryan D Cassaday, et al.
JAMA|June 11, 2009
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trialsJohn Koreth, Richard Schlenk, Kenneth J Kopecky, et al.
Leukemia Research|March 27, 2026
Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025Hetty E Carraway, Daniel J DeAngelo, Eunice S Wang, et al.
Blood Vessels, Thrombosis & Hemostasis|August 6, 2025
Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomesJoan How, Orly Leiva, Robert Redd, et al.
Pageof 28